304 related articles for article (PubMed ID: 30796178)
21. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
22. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
23. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis.
Di Stefano V; Rinaldo C; Sacchi A; Soddu S; D'Orazi G
Exp Cell Res; 2004 Feb; 293(2):311-20. PubMed ID: 14729469
[TBL] [Abstract][Full Text] [Related]
24. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
25. Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization.
Polonio-Vallon T; Kirkpatrick J; Krijgsveld J; Hofmann TG
Cell Cycle; 2014; 13(1):115-25. PubMed ID: 24196445
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
27. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
28. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
Nardinocchi L; Puca R; Givol D; D'Orazi G
Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
[TBL] [Abstract][Full Text] [Related]
29. Interplay between Mdm2 and HIPK2 in the DNA damage response.
Zhang XP; Liu F; Wang W
J R Soc Interface; 2014 Jul; 11(96):. PubMed ID: 24829283
[TBL] [Abstract][Full Text] [Related]
30. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
31. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313.
Lee MG; Han J; Jeong SI; Her NG; Lee JH; Ha TK; Kang MJ; Ryu BK; Chi SG
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15532-7. PubMed ID: 25313037
[TBL] [Abstract][Full Text] [Related]
32. PARP1 regulates the protein stability and proapoptotic function of HIPK2.
Choi JR; Shin KS; Choi CY; Kang SJ
Cell Death Dis; 2016 Oct; 7(10):e2438. PubMed ID: 27787517
[TBL] [Abstract][Full Text] [Related]
33. DAZAP2 acts as specifier of the p53 response to DNA damage.
Liebl MC; Moehlenbrink J; Becker H; Raddatz G; Abdeen SK; Aqeilan RI; Lyko F; Hofmann TG
Nucleic Acids Res; 2021 Mar; 49(5):2759-2776. PubMed ID: 33591310
[TBL] [Abstract][Full Text] [Related]
34. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
35. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
[TBL] [Abstract][Full Text] [Related]
36. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.
Batista LF; Roos WP; Christmann M; Menck CF; Kaina B
Cancer Res; 2007 Dec; 67(24):11886-95. PubMed ID: 18089819
[TBL] [Abstract][Full Text] [Related]
37. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
38. Hyperglycemia triggers HIPK2 protein degradation.
Baldari S; Garufi A; Granato M; Cuomo L; Pistritto G; Cirone M; D'Orazi G
Oncotarget; 2017 Jan; 8(1):1190-1203. PubMed ID: 27901482
[TBL] [Abstract][Full Text] [Related]
39. HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.
Li H; Li J; Chen L; Qi S; Yu S; Weng Z; Hu Z; Zhou Q; Xin Z; Shi L; Ma L; Huang A; Lu Y
Clin Cancer Res; 2019 Jun; 25(12):3602-3616. PubMed ID: 30862693
[TBL] [Abstract][Full Text] [Related]
40. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.
Cecchinelli B; Lavra L; Rinaldo C; Iacovelli S; Gurtner A; Gasbarri A; Ulivieri A; Del Prete F; Trovato M; Piaggio G; Bartolazzi A; Soddu S; Sciacchitano S
Mol Cell Biol; 2006 Jun; 26(12):4746-57. PubMed ID: 16738336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
